Skip to content
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
BioTechGrid BioTechGrid
  • Home
  • Biotechnology
  • Medical Technology
  • Research
  • Genetics
  • Press Releases
    • Business Wire
    • GlobeNewswire
    • PRNewswire
  • Contact
  • Home
  • Biotechnology
  • Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui

Braveheart charges past expectations with $382.5M IPO to fund cardio drug from Hengrui

August 6, 2026Posted inBiotechnology

Braveheart Bio has overcome its own IPO expectations, rallying $382.5 million in an upsized listing to fund its cardiovascular ambitions.

Post navigation

Previous Post
no-till-and-microbial-fertilizers-jointly-boost-carbon-storage-in-nutrient-poor-albic-soils No-till and microbial fertilizers jointly boost carbon storage in nutrient-poor albic soils
Next Post
Neural precursor divides into two cell lineages earlier than expected neural-precursor-divides-into-two-cell-lineages-earlier-than-expected

Recent Posts

  • Automated CT body composition markers show limited survival-prediction gains
  • Free-electron laser demonstrates attosecond hard X-ray pulses
  • Half of head and neck cancer survivors report clinically relevant fatigue
  • Review maps antioxidant biohybrid matrices for organ repair
  • NiCo–TiO2 catalyst lowers hydrogen-evolution overpotential in alkaline testing

Archives

  • October 2026
  • September 2026
  • August 2026
  • July 2026
  • September 2024
  • August 2024
  • March 2024
  • September 2023

Privacy Policy    Terms

Scroll to Top